C/EBPβ promotes angiogenesis through secretion of IL-6, which is inhibited by genistein, in EGFRvIII-positive glioblastoma

International Journal of Cancer

Volumn 136, Issue 11, 2015, Pages 2524-2534

  Liu, Xujie ^a,b   Liu, Kaiyu ^a   Qin, Jiazhen ^c   Hao, Limin ^d   Li, Xiaoxia ^a   Liu, Yinan ^a,b   Zhang, Xiaoyan ^a,b   Liu, Xiuxiu ^a,b   Li, Peng ^a,b   Han, Shuo ^a,b   Mao, Zebin ^a   Shen, Li ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d Beijing Scilight Biotechnology Ltd Co   (China)

Author keywords

angiogenesis; C EBP ; EGFRvIII; GBM; IL 6

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GENISTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INTERLEUKIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PROMOTER REGION; SECRETION (PROCESS); TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE, TUMOR; ERBB RECEPTORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; GLIOBLASTOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTOR CHOP; TUMOR MICROENVIRONMENT;

EID: 84924872172     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29319     Document Type: Article

References (50)

1. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-6.
2. Grandis JR, Tweardy DJ,. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-84.
3. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997; 272: 2927-35.
4. Ongkeko WM, Altuna X, Weisman RA, et al. Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 2005; 124: 71-6.
5. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
6. Ekstrand AJ, Sugawa N, James CD, et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 1992; 89: 4309-13.
7. Malden LT, Novak U, Kaye AH, et al. Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. Cancer Res 1988; 48: 2711-14.
8. Sugawa N, Ekstrand AJ, James CD, et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990; 87: 8602-6.
9. Yamazaki H, Fukui Y, Ueyama Y, et al. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol 1988; 8: 1816-20.
10. Damstrup L, Wandahl Pedersen M, Bastholm L, et al. Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype. Int J Cancer 2002; 97: 7-14.
11. Nagane M, Coufal F, Lin H, et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996; 56: 5079-86.
12. Pedersen MW, Tkach V, Pedersen N, et al. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer 2004; 108: 643-53.
13. Tang CK, Gong XQ, Moscatello DK, et al. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 2000; 60: 3081-7.
14. Liu XJ, Wu WT, Wu WH, et al. A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance. CNS Neurosci Ther 2013; 19: 494-502.
15. Massoud TF, Gambhir SS,. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003; 17: 545-80.
16. Gambhir SS,. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2: 683-93.
17. Inda MM, Bonavia R, Mukasa A, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010; 24: 1731-45.
18. Brooks PC, Clark RA, Cheresh DA,. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-71.
19. Kumar CC,. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003; 4: 123-31.
20. Eliceiri BP, Cheresh DA,. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999; 103: 1227-30.
21. Kutner RH, Zhang XY, Reiser J,. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 2009; 4: 495-505.
22. Zhuo de X, Niu XH, Chen YC, et al. Vitamin D3 up-regulated protein 1(VDUP1) is regulated by FOXO3A and miR-17-5p at the transcriptional and post-transcriptional levels, respectively, in senescent fibroblasts. J Biol Chem 2010; 285: 31491-501.
23. Li X, Han Y, Pang W, et al. AMP-activated protein kinase promotes the differentiation of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008; 28: 1789-95.
24. Carey MF, Peterson CL, Smale ST,. Chromatin immunoprecipitation (ChIP). Cold Spring Harb Protoc 2009; 2009: pdb prot5279.
25. Zhang J, Sarkar S, Cua R, et al. A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis 2012; 33: 312-19.
26. Sun Y, Nelson PS,. Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin Cancer Res 2012; 18: 4019-25.
27. Demirci U, Yaman M, Buyukberber S, et al. Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy. Int Immunopharmacol 2012; 14: 546-9.
28. Choi KS, Song H, Kim EH, et al. Inhibition of hydrogen sulfide-induced angiogenesis and inflammation in vascular endothelial cells: potential mechanisms of gastric cancer prevention by Korean Red Ginseng. J Ginseng Res 2012; 36: 135-45.
29. Ron D, Habener JF,. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 1992; 6: 439-53.
30. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262: 5592-5.
31. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994; 91: 7727-31.
32. Neman J, Jandial R,. Translational emphasis: hypoxia and vasculogenesis in glioma recurrence. Neurosurgery 2010; 66: N20-1.
33. Babu H, Tse V,. Glioma stem cells give rise to tumor endothelium: de novo vasculogenesis? World Neurosurg 2011; 75: 174-5.
34. Bergers G, Benjamin LE,. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10.
35. Folkman J,. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971; 285: 1182-6.
36. Bartels U, Hawkins C, Jing M, et al. Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas. J Neurosurg 2006; 104: 314-20.
37. Sie M, de Bont ES, Scherpen FJ, et al. Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma? Neuropathol Appl Neurobiol 2010; 36: 636-47.
38. Barth RF, Yang W, Adams DM, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res 2002; 62: 3159-66.
39. Vajkoczy P, Farhadi M, Gaumann A, et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 2002; 109: 777-85.
40. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
41. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-8.
42. Chang AJ, Sohn R, Lu ZH, et al. Detection of rapalog-mediated therapeutic response in renal cancer xenografts using (6)(4)Cu-bevacizumab immunoPET. PLoS One 2013; 8: e58949.
43. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007; 48: 1313-19.
44. Nagengast WB, Hooge MN, van Straten EM, et al. VEGF-SPECT with (1)(1)(1)In-bevacizumab in stage III/IV melanoma patients. Eur J Cancer 2011; 47: 1595-602.
45. Nayak TK, Garmestani K, Baidoo KE, et al. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A"-DTPA-bevacizumab. Int J Cancer 2011; 128: 920-6.
46. Stollman TH, Scheer MG, Leenders WP, et al. Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer 2008; 122: 2310-14.
47. Liu Z, Sun X, Liu H, et al. Early assessment of tumor response to gefitinib treatment by noninvasive optical imaging of tumor vascular endothelial growth factor expression in animal models. J Nucl Med 2014; 55: 818-23.
48. Wu AM, Olafsen T,. Antibodies for molecular imaging of cancer. Cancer J 2008; 14: 191-7.
49. Zhang Y, Hong H, Orbay H, et al. PET imaging of CD105/endoglin expression with a (6)(1)/(6)(4)Cu-labeled Fab antibody fragment. Eur J Nucl Med Mol Imaging 2013; 40: 759-67.
50. Takai T,. Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 2005; 25: 1-18.